Boston Scientific Corporation (NYSE: BSX) has announced the acquisition of Obsidio, Inc., a privately-held company that has developed the Gel Embolic Material (GEM™) technology used for embolization of blood vessels in the peripheral vasculature.
Latham & Watkins LLP represents Boston Scientific Corporation in the transaction with a corporate deal team led by Boston partner Julie Scallen, with Boston associates Stefanie Vincent, Michael Casagrande, Andrew Rondeau, and Nicole Angelica. Advice was also provided on tax matters by Washington, D.C. partner Nicholas DeNovio, with Washington, D.C. associates Pierce Pandolph and Emmanuel Kassim; on benefits and employment matters by Chicago partner Benjamin Rosemergy, with Chicago associate Daniel Gocek; and on healthcare regulatory matters by Washington, D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
The advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
